»GeNeuro: publication in the scientific journal Multiple Sclerosis of the results of the CHANGE-MS and ANGEL-MS clinical studies MyPharma Editions
Posted on Thursday, July 15, 2021 GeNeuro, a biopharmaceutical company developing new treatments for neurodegenerative diseases such as multiple sclerosis (MS), has announced the publication in the scientific journal Multiple Sclerosis of safety and efficacy results from the CHANGE-MS and ANGEL- clinical trials. MS with temelimab. These studies were a 48-week, double-blind, Phase 2 trial … Read more